Almost five months after the US Centers for Disease Control and Prevention decided to preferentially favor mRNA COVID-19 vaccines over Janssen Biotech Inc.’s adenovirus-based product, the Food and Drug Administration has followed suit, citing the latter’s risks of thrombosis with thrombocytopenia syndrome.
On 5 May, the FDA announced it was limiting authorization to individuals ≥18 years for whom other authorized or approved...







